Alza 36 contains 36 mg Methylphenidate, aka by the brand name "Ritalin". This tablet is sold under the brand name "Concerta".
Organic chemistry is a chemistry subdiscipline involving the scientific study of the structure, properties, and reactions of organic compounds and organic materials, i.e., matter in its various forms that contain carbon atoms. Study of structure includes using spectroscopy and other physical and chemical methods to determine the chemical composition and constitution of organic compounds and materials. Study of properties includes both physical properties and chemical properties, and uses similar methods as well as methods to evaluate chemical reactivity, with the aim to understand the behavior of the organic matter in its pure form (when possible), but also in solutions, mixtures, and fabricated forms. The study of organic reactions includes both their preparation—by synthesis or by other means—as well as their subsequent reactivities, both in the laboratory and via theoretical (in silico) study.
The range of chemicals studied in organic chemistry include hydrocarbons, compounds containing only carbon and hydrogen, as well as compositions based on carbon but containing other elements. Organic chemistry overlaps with many areas including medicinal chemistry, biochemistry, organometallic chemistry, and polymer chemistry, as well as many aspects of materials science.
Drug subcultures are examples of countercultures that are primarily defined by recreational drug use.
Drug subcultures are groups of people united by a common understanding of the meaning and value (good or otherwise) of the incorporation into one's life of the drug in question. Such unity can take many forms, from friends who take the drug together, possibly obeying certain rules of etiquette, groups banding together to help each other obtain drugs and avoid arrest to full-scale political movements for the reform of drug laws. The sum of these parts can be considered an individual drug's "culture".
Alza Corporation was a pharmaceutical and medical systems company founded in 1968 by Dr Alejandro Zaffaroni; the company's name is a portmanteau of his name. Alza pioneered the field of drug delivery systems, bringing over 20 prescription pharmaceutical products to market, and employing about 10,000 people during 20 years.]citation needed[ Alza was acquired by Johnson & Johnson in May 2001, in a stock-for-stock transaction worth US$10.5 billion.]citation needed[
The company owns the patents on the following delivery platforms:
Attention-deficit hyperactivity disorder
OROS (Osmotic [Controlled] Release Oral [Delivery] System) is a controlled release oral drug delivery system in the form of a tablet. The tablet has a rigid water-permeable jacket with one or more laser drilled small holes. As the tablet passes through the body, the osmotic pressure of water entering the tablet pushes the active drug through the opening in the tablet.
OROS is a trademarked name owned by Alza Corporation. OROS medications include:
Health Medical Pharma
Health Medical Pharma
Attention deficit hyperactivity disorder (ADHD, similar to hyperkinetic disorder in the ICD-10) is a psychiatric disorder of the neurodevelopmental type in which there are significant problems of attention and/or hyperactivity and acting impulsively that are not appropriate for a person's age. These symptoms must begin by age six to twelve and be present for more than six months for a diagnosis to be made. In school-aged individuals the lack of focus may result in poor school performance.
Despite being the most commonly studied and diagnosed psychiatric disorder in children and adolescents, the cause in the majority of cases is unknown. It affects about 6 to 7 percent of children when diagnosed via the DSM-IV criteria and 1 to 2 percent when diagnosed via the ICD-10 criteria. Rates are similar between countries and depend mostly on how it is diagnosed. ADHD is approximately three times more frequent in boys than in girls. About 30 to 50 percent of people diagnosed in childhood continue to have symptoms into adulthood and between 2 and 5 percent of adults have the condition. The condition can be difficult to tell apart from other disorders as well as that of high normal activity.